Therapeutic efficacy and safety of a human fusion construct targeting the TWEAK receptor Fn14 and containing a modified granzyme B

BACKGROUND: Antibody-drug conjugates are an exceptional and useful therapeutic tool for multiple diseases, particularly for cancer treatment. We previously showed that the fusion of the serine protease granzyme B (GrB), the effector molecule or T and B cells, to a binding domain allows the controlle...

Descripción completa

Detalles Bibliográficos
Autores principales: Alvarez de Cienfuegos, Ana, Cheung, Lawrence H, Mohamedali, Khalid A, Whitsett, Timothy G, Winkles, Jeffrey A, Hittelman, Walter N, Rosenblum, Michael G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Oncolytic and Local Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7507898/
https://www.ncbi.nlm.nih.gov/pubmed/32958685
http://dx.doi.org/10.1136/jitc-2020-001138

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7507898/
https://www.ncbi.nlm.nih.gov/pubmed/32958685
http://dx.doi.org/10.1136/jitc-2020-001138

Ejemplares similares